Availability of Free Drug Provision for Patients with Type 2 Diabetes at the Outpatient Level in the Republic of Kazakhstan

Abstract

The purpose of the study: To analyze the availability of free drug provision for patients with type 2 diabetes at the outpatient level in the Republic of Kazakhstan.

Methods: in this work, a comparative analysis of the drug provision of patients with type 2 diabetes mellitus was carried out within the framework of the list of outpatient drug provision and the clinical protocol for the treatment of type 2 diabetes mellitus. A pharmacoeconomic analysis was also carried out in terms of calculating the annual cost of pharmacotherapy with drugs for the treatment of type 2 diabetes mellitus.

Results. 42 types of medicines are included in the clinical protocol for the treatment of type 2 diabetes mellitus, of which 24 international nonproprietary names for the treatment of type 2 diabetes are included in the List of free outpatient drug provision (6 oral combinations are also possible). Thus, patients with type 2 diabetes mellitus in the Republic of Kazakhstan have access to 71% of medicines from the clinical protocol for free drug provision.

The cost of annual therapy with sitagliptin and alogpliptin is cheaper than analogues, and the results of efficacy and safety are comparable, the inclusion of these drugs in the list of free drug provision will also make it possible to make 2 oral combinations, which will increase the availability of free outpatient drug provision for patients with type 2 diabetes mellitus, and increase this show up to 81%.

Conclusions. For patients with type 2 diabetes, 30 types of drugs are available for free outpatient drug provision, which is 71% of the drugs included in the clinical protocol.

To increase accessibility, we consider it appropriate to include the drug alogliptin in the list of outpatient drug provision.